Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type2diabetes
Phase PHASE4
Enrollment 196
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4 inhibitor in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and DPP-4 inhibitor(KLIMT Study)

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Drug: DW6012(Dasidiem tab. 10/100mg) — Once a day, Oral administration

Primary Outcomes

  • Variance in HbA1c from baseline to 24 weeks on study drug (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-05-28
Completion: 2025-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 196 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dong Wha Pharmaceutical Co. Ltd.
Contact Information
Study Contact:
Kyung Hee University Hospital at Gangdong
82+2-440-7000
cri@khnmc.or.kr
Kyung Hee University Hospital at Gangdong
Interventions
  • Drug: DW6012(Dasidiem tab. 10/100mg) — Once a day, Oral administration
Study Locations (1 sites)
Kyung Hee University Hospital at Gangdong, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Patients with type 2 diabetes who are 19 years of age or older at the date of written consent * Subjects who Receiving a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks at the time of screening * HbA1c ≤ 7.0% ≤ HbA1c \< 10% at time of screening * BMI ≤ 18.5 kg/m2 ≤ 40 kg/m2 at time of screening * Subjects fully explained and understood the purpose and methods of this study and voluntarily gave written informed consent Exclusion Criteria: * Patients with type 1 diabetes * Have a BMI \> 40 kg/m2 * Subjects who have moderate (Stage 3b) or severe kidney disease or an estimated glomerular filtration rate (eGFR, using the CKD-EPI formula) \< 45 mL/min/1.73 m2 * Patients with end stage renal disease or patients on dialysis * Patients with uncontrolled heart failure (NYHA class III - IV) * Patients with history of uncontrolled arrhythmia, myocardial infarction, unstable angina, coronary artery bypass graft surgery, cerebrovascular disease within 24 weeks prior to the screening visit * Patients with acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis (DKA) with or without coma, and patients with a history of ketoacidosis * Patients with diabetic coma or precoma * Patients with a history of severe hypoglycemia while taking metformin and DPP-4 inhibitors. * Patients with hematuria * Patients who receiving treatment for thyroid dysfunction at the time of screening * Malnourished, starving, or debilitated subjects * Patients with pituitary insufficiency or adrenal insufficiency * Patients with clinically significant hepatic disease with AST or ALT greater than 3 times the upper limit of normal * Patients with severe infectious diseases, perioperative, or clinically significant trauma * Have a history of substance abuse * Patients receiving insulin or sulfonylurea, thiazolidinedione, SGLT2 inhibitor, GLP-1 receptor agonist within 8 weeks prior to the screening visit * Patients who have received more than 2 consecutive weeks of corticosteroids within 8 weeks at the time of screening or who require treatment requiring repeated use of corticosteroids * Patients with a history of malignancy within the last 5 years * Participation in any other clinical trial within 12 weeks of screening in which an investigational drug or investigational medical device was administered or applied * Pregnant and breastfeeding women * Hypersensitivity to any of the drugs and components, including metformin, DPP-4 inhibitors, dapagliflozin, TZDs, sulfonylurea class of drugs, or any of the ingredients * Patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose mal-absorption. * Any other person deemed by the investigator to be unsuitable for participation in the study
Conditions HER2-negative Breast Cancer, Recurrence,...
Phase Not Applicable
Enrollment 500
Locations 19 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multi-center observational real-world study, with a total of 500 patients planned to be enrolled. This study is divided into two cohorts: the triple-negative breast cancer (TNBC) cohort and the hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer (HR+/ HER2-BC) cohort. The aim of this study is to assess the efficacy and safety of Sacituzumab Tirumotecan (SKB264) monotherapy or combination therapy in patients with unresectable locally advanced, recurrent or metastatic HER2-negative breast cancer in the real-world setting.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: SKB264 Monotherapy or Combination Therapy — The interventions in this study comprised SKB264 monotherapy or combination therapy involving SKB264. The specific combination regimens were determined based on real-world clinical practice.

Primary Outcomes

  • Time to next treatment (TTNT) of SKB264 monotherapy or combination therapy in patients with unresectable locally advanced, recurrent or metastatic HER2-negative breast cancer (Time from initiation of SKB264 monotherapy or combination therapy to start of next treatment, assessed up to 24 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-28
Completion: 2027-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Xue Wang, M.D.
86-010-87787242
wxyxyuki@163.com
Fanfan Li
The Second Affiliated Hospital of Anhui Medical University
Xue Wang
86-010-87787242
wxyxyuki@163.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: SKB264 Monotherapy or Combination Therapy — The interventions in this study comprised SKB264 monotherapy or combination therapy involving SKB264. The specific combination regimens were determined based on real-world clinical practice.
Study Locations (19 sites)
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601 China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Peking University First Hospital, Beijing, Beijing Municipality 100034 China
Chinese PLA General Hospital, Beijing, Beijing Municipality 100853 China
Fujian Cancer Hospital, Fuzhou, Fujian 350000 China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei China
The Third People's Hospital of Zhengzhou, Zhengzhou, Henan 450000 China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan China
Taihe Hospital, Shiyan, Hubei 442099 China
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥ 18 years old at the time of signing the informed consent form, regardless of gender; 2. Patient must meet one of the following pathological diagnoses and classifications: 2.1) For TNBC Cohort: -Histological/cytological confirmed of triple-negative breast cancer (TNBC) from the most recent pre-SKB264 biopsy/pathological report, with: HER2 negative: immunohistochemistry (IHC) of 0 or 1+; if is 2+ by IHC, negative HER2 expression must be confirmed by fluorescence in situ hybridization (FISH); Estrogen and progesterone receptor negative means that less than 1% of the cells express hormone receptors as indicated by IHC; -Locally advanced, recurrent, or metastatic disease (locally advanced disease should be confirmed by investigators as ineligible for curative resection); 2.2) For HR+/HER2- BC Cohort: -Histological/cytological confirmed of HR+/HER2- breast cancer from the most recent pre-SKB264 biopsy/pathological report, with: HER2 negative: IHC of 0 or 1+; if is 2+ by IHC, negative HER2 expression must be confirmed by FISH; HR positive: Hormone receptor-positive (HR, ER, or PR status) was defined as ≥1% expression by IHC.-Locally advanced, recurrent, or metastatic disease (locally advanced disease should be confirmed by investigators as ineligible for curative resection); 3. Plan to receive SKB264 monotherapy or combination therapy; 4. Prior treatment lines: -For TNBC Cohort: ≤2 lines of systemic antitumor therapy for unresectable locally advanced, recurrent, or metastatic disease; -For HR+/HER2- BC Cohort: ≤2 lines of systemic antitumor therapy (excluding endocrine therapy) for unresectable locally advanced, recurrent, or metastatic disease; 5. Voluntarily participate in the study, sign the informed consent form and demonstrate good compliance. Exclusion Criteria: 1. Patients with other malignancies, except cured basal or squamous cell skin cancer or in situ cancer of cervix; and patients with other malignancies must have a tumor-free period of at least 5 years; 2. Patients who are currently participating in other interventional clinical studies; 3. Known allergy to the investigational drug or any of its components; 4. Pregnant or lactating women; 5. Any situation that the researchers consider to interfere with the evaluation of the study drug or the safety of the subjects or the analysis of the study results, or any other situation that the researchers consider inappropriate to participate in this study.
Conditions Pulmonary Arterial Hypertension (PAH), P...
Phase Not Applicable
Enrollment 139
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study \--- Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease that affects the arteries of the lungs and the right side of the heart. Early diagnosis is essential to initiate appropriate treatment and improve patient outcomes. However, worldwide studies show that there is often a significant delay between the onset of symptoms and the final diagnosis. This delay may lead to disease progression and worse survival. This multicenter observational study aims to understand the time from the first symptoms to the diagnosis of PAH and other rare diseases across several Brazilian reference centers. By analyzing medical records and patient journeys, the investigators intends to identify factors contributing to delayed diagnosis and potential opportunities for earlier detection. The study includes adult patients diagnosed with PAH or other selected rare diseases within the last five years. The investigators will analyze time to diagnosis, number and type of physicians consulted, tests performed, and possible misdiagnoses. Our goal is to support the development of strategies that reduce diagnostic delay and improve access to specialized care for people living with rare diseases. This study does not involve any intervention and poses no additional risk to participants, as it is based solely on retrospective data from medical records.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: There will be no intervention — There will be no intervention

Primary Outcomes

  • Time from Symptom Onset to Confirmed Diagnosis of Group 1 Pulmonary Arterial Hypertension (From date of first reported symptom potentially related to PAH until the date of confirmed diagnosis by right heart catheterization, assessed up to 60 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-07
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 139 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Contact Information
Study Contact:
Caio Fernandes, PhD
+55 11 2661-1548
caio.cesar@hc.fm.usp.br
Caio Fernandes
PhD
caio.cesar@hc.fm.usp.br
InCor - Universidade de São Paulo
Interventions
  • Other: There will be no intervention — There will be no intervention
Study Locations (1 sites)
InCor - Universidade de São Paulo, São Paulo, São Paulo 05048000 Brazil
Eligibility Criteria
Inclusion Criteria: * Availability of documented or estimated date of first symptom suggestive of PAH. * Availability of documented date of confirmed PAH diagnosis. Exclusion Criteria: * Patients with pulmonary hypertension not classified as Group 1 (e.g., due to left heart disease, chronic lung disease, or chronic thromboembolic disease). * Patients with insufficient data to determine either the date of symptom onset or the date of confirmed diagnosis. * Patients diagnosed only clinically or by echocardiography, without confirmation by right heart catheterization.
Conditions Type 2 Diabetes Mellitus, Non Insulin De...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Recent studies show that lifestyle interventions, such as exercise, healthy diet, and education, can help prevent type 2 diabetes in high-risk individuals, and even reverse the disease in its early stages. However, not many methods have been developed to use modern technology to help people manage their diabetes in a more active way, in line with participatory medicine, where patients play a key role in their treatment. In this study, the investigators propose an e-health approach to automatically collect health data from patients, including information from continuous glucose monitor (CGM) and other health tracking devices, in real-life conditions. The investigators will also develop a simple and easy-to-understand tool to track patient's metabolic status and will analyze how it relates to lifestyle changes using the data collected during the study. Twenty sedentary individuals with type 2 diabetes, not on insulin treatment, will take part in the trial. All patients will be monitored for two weeks using a CGM device and an activity tracker. During the first week, participants will follow their normal daily routine, while in the second week, subjects will be asked to engage in moderate physical activity every day, consisting of walking. At the end of each week, patients will take a meal tolerance test. The main goal of the study is to measure how blood sugar levels change over the two weeks, also evaluating the impact of individuals' daily activities like exercise on it. The research team will develop and use mathematical models to measure this change. A secondary goal is to evaluate the ease of use of the e-health system for data collection.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Physical activity intervention — In the first week, patients will be asked to maintain their normal sedentary life, spending most of the waking day sitting. During the second week, participants will be asked to take at least 10,000 steps/day, with sitting replaced by standing and light-intensity walking. See doi: 10.1007/s00125-016-4161-7

Primary Outcomes

  • Change in Blood Glucose Control Over the Two Study Weeks (From enrollment to the end of the treatment at 2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05
Completion: 2026-01-15
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Enea Parimbelli
Collaborators: Istituti Clinici Scientifici Maugeri SpA, University of Padova
Contact Information
Study Contact:
Enea Parimbelli
+39 0382 9895981
enea.parimbelli@unipv.it
Interventions
  • Behavioral: Physical activity intervention — In the first week, patients will be asked to maintain their normal sedentary life, spending most of the waking day sitting. During the second week, participants will be asked to take at least 10,000 steps/day, with sitting replaced by standing and light-intensity walking. See doi: 10.1007/s00125-016-4161-7
Study Locations (1 sites)
Istituti Clinici Scientifici Maugeri di Pavia, Pavia, Pavia 27100 Italy
Eligibility Criteria
Inclusion Criteria: * Non-insulin treated T2D diagnosis (not treated at all or only with metformin); * Physically inactive (less than 150 minutes/week of moderate physical activity); * Age between 40 and 70; * HbA1c below 8.5%. Exclusion Criteria: * Diabetes diagnosis less than 3 years before the study initiation; * Pregnancy; * Symptomatic heart disease, e.g. history of myocardial infarction, coronary bypass, stenting procedure, angina, or any ischemic cerebrovascular event; * Use of a medication that significantly impacts glucose metabolism (oral steroids); * Use of a medication that significantly lowers heart rate (beta blockers, reserpine, guanethidine, methyldopa, clonidine, cimetidine, digitalis, calcium channel blockers, amiodarone, antiarrhythmic drugs, or lithium); * Atrial fibrillation; * Use of an electronic pacemaker.
Conditions Major Depressive Disorder
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is one of the most common psychiatric disorders, characterized by extremely high prevalence, relapse rate and therapeutic resistance. Treatment with ketamine and its enantiomer esketamine is the next step towards the successful treatment and understanding of depression that is resistant to treatment with standard antidepressants. The proposed study will include approximately 50 patients with MDD and 50 healthy control subjects of both sexes. Using untargeted metabolomic approach, we plan to detect changes in biochemical pathways related to the diagnosis of treatment-resistant MDD and changes related to the mechanism of action of esketamine. The proposed research will contribute to further understanding of the mechanism of action of esketamine in patients with MDD. Metabolic changes will be associated with improvements in specific domains of depressive symptoms and symptom severity in subjects with treatment-resistant major depressive disorder.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Drug: Esketamine — nasal

Primary Outcomes

  • changed metabolomics (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Zagreb
Principal Investigators:
  • Tea Fabijanić, MD (PRINCIPAL_INVESTIGATOR) - University of Zagreb
Contact Information
Study Contact:
Tea Fabijanić, MD
+385915698801
tea.fabijan@gmail.com
Tea Fabijanić
+385915698801
tea.fabijan@gmail.com
Tea Fabijanić
Interventions
  • Drug: Esketamine — nasal
Study Locations (1 sites)
Tea Fabijanić, Zagreb, Croatia
Eligibility Criteria
Inclusion Criteria: * for healthy control participants: 18-70 years, both sexes, without psychiatric drugs * for patients: from 18- 70 years, both sexes, failed treatment attempts with at least two antidepressants of the appropriate dose and duration. Exclusion Criteria: * for patients: treatment with tryptophan, St. John's wort, and/or opioid analgesics in the last month, daily intake of benzodiazepines; * for all participants: presence of psychotic symptoms, alcohol and/or drug addiction, disorder seizures, eating disorder, dementia and other neurodegenerative diseases, epilepsy, intellectual disabilities, severe somatic diseases (including insufficiently controlled arterial hypertension, diabetes and thyroid diseases), active psychotherapeutic treatment (except supportive psychotherapy, which is an integral part of every psychiatric treatment and will be the same in all groups of respondents). Participants will be excluded if they follow a weight loss diet or take weight loss medication, are pregnant or breastfeeding.
Conditions Breast Cancer
Phase PHASE1
Enrollment 33
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Drug: Azelaic Acid — A thin layer of Azelaic acid should be applied to the entire area of radiation treatment twice daily, each day of the week (including weekends) starting one week prior to the start of radiation, then during the entire course of radiation treatment (usually 3-5 weeks), and for 3 weeks following the completion of radiation treatment.

Primary Outcomes

  • Determine the feasibility of twice daily use of topical azelaic acid in patients undergoing breast radiation therapy (One week prior to radiation treatment, daily during radiation treatment up to 5 weeks, three weeks following radiation treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-13
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 33 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Virginia Commonwealth University
Principal Investigators:
  • Todd C. Adams, MD (PRINCIPAL_INVESTIGATOR) - Virginia Commonwealth University
Contact Information
Study Contact:
Massey IIT Research Operations
804-628-6430
masseyepd@vcu.edu
Massey CTO CPC Team
804-628-6430
MasseyCPC@vcu.edu
Virginia Commonwealth University
Todd C. Adams, MD
Virginia Commonwealth University
Interventions
  • Drug: Azelaic Acid — A thin layer of Azelaic acid should be applied to the entire area of radiation treatment twice daily, each day of the week (including weekends) starting one week prior to the start of radiation, then during the entire course of radiation treatment (usually 3-5 weeks), and for 3 weeks following the completion of radiation treatment.
Study Locations (1 sites)
Virginia Commonwealth University, Richmond, Virginia 23298 United States
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years * Self-reports as Black, Asian, Hispanic/Latin, ethnically originating from the Mediterranean rim or Pacific rim, or she/he tans easily in the sun * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 (Appendix 1, Section 18) * Attestation by the patient that she/he is not pregnant, lactating, or planning to become pregnant, or planning to father a baby during the study period * Histologic confirmation of breast malignancy (with TNM staging) If the patient did not receive adjuvant chemotherapy, adjuvant radiation must start within 180 days of lumpectomy or mastectomy. If the patient received adjuvant chemotherapy, adjuvant radiation should start within 60 days of the last dose of chemotherapy * Treatment plan includes one of the following: * Conventionally fractionated whole breast radiation (45-50 Gray in 25 fractions) * Moderately hypofractionated whole breast radiation (42.56 Gray in 16 fractions or 40 Gray in 15 fractions) * Conventionally fractionated chest wall radiation (45-50 Gray in 25 fractions) * Partial breast radiation (42.56 Gray in 16 fractions, 40 Gray in 15 fractions, or 30 Gray in 5 fractions) if using 3D conformal radiation or if the tumor is located close to the skin surface * Treatment of the regional lymph nodes, a tumor bed boost (4-8 fractions), and use of tissue-equivalent bolus on the chest wall may be included at the discretion of the treating physician. * Radiation will be photon-based. Note: If the patient receives a boost, photons and/or electrons may be used at the discretion of the treating physician. Exclusion Criteria: * Prior radiotherapy to any portion of the planned treatment site * Current inflammatory breast cancer or gross dermal involvement at initiation of radiotherapy * Concomitant immunotherapy or cytotoxic chemotherapy. Concomitant HER2 directed therapy or concomitant endocrine therapy is allowed * Active rash or dermatitis within the treatment field, or a history of any rash or dermatologic condition within the treatment field * Active collagen vascular diseases (ie lupus erythematosus, scleroderma, dermatomyositis) * History of organ transplant or bone marrow transplant * History of hypersensitivity or allergic reaction to any ingredients in the topical azelaic acid formulation * Has used within 28 days prior to baseline: * topical retinoids to the breast * oral retinoids * systemic (oral or injectable) antibiotics known to have an impact on the severity of skin rash or sun-sensitivity (eg, containing tetracycline and its derivatives, erythromycin and its derivatives, sulfamethoxazole, or trimethoprim) * systemic corticosteroids or immunosuppressive drugs, except as part of standard chemotherapy treatment or used for an IV contrast allergy * Has used on treated breast within 2 weeks prior to baseline: * topical corticosteroids * topical antibiotics * topical medications for skin rash (eg, metronidazole, azelaic acid) * Radiation therapy will be proton therapy or carbon therapy * External beam partial breast irradiation, brachytherapy partial breast irradiation, or intraoperative radiation are included in the treatment plan Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
Conditions Postoperative Period, Lung Cancer (Diagn...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled clinical trial aims to evaluate the effects of an 8-week tele-yoga intervention in individuals with lung cancer who have undergone lung resection surgery. The intervention group will receive supervised yoga sessions via online synchronous video conferencing, while the control group will continue with standard post-operative care. The primary outcome is exercise capacity (6-minute walk test), with secondary outcomes including pulmonary function, respiratory and peripheral muscle strength, physical activity level, dyspnea, fatigue, sleep quality, anxiety and depression, and quality of life. It is hypothesized that tele-yoga will improve physical and psychological recovery post-surgery and may serve as a feasible home-based pulmonary rehabilitation alternative.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Tele-Yoga Training — The Tele-yoga group will participate in real-time yoga sessions three times a week for eight weeks, including individual sessions for the first two weeks and small group sessions for the remaining six weeks, with all sessions supervised by a certified instructor. Each session will last approximately 45-60 minutes and include a 5-10 minute warm-up, 15-20 minutes of yoga postures, 15-20 minutes of yogic breathing exercises, and 5-10 minutes of relaxation and meditation.

Primary Outcomes

  • The Six-Minute Walk Test (6MWT) (Change from Baseline at 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-10
Completion: 2026-10-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul University
Principal Investigators:
  • Rengin Demir, Prof (PRINCIPAL_INVESTIGATOR) - Istanbul University - Cerrahpasa
  • Akif Turna, Prof (PRINCIPAL_INVESTIGATOR) - Istanbul University - Cerrahpasa
  • Sevde B Kara, PhD student (PRINCIPAL_INVESTIGATOR) - Istanbul University - Cerrahpasa
Contact Information
Study Contact:
Sevde B Kara, PhD Student
+90 544 257 72 85
sevdebetulyigit@gmail.com
Akif Turna, Prof
+90 505 258 15 81
akif.turna@gmail.com
Akif Turna, Prof
+90 505 258 15 81
akif.turna@gmail.com
Department of Thoracic Surgery, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa
Interventions
  • Other: Tele-Yoga Training — The Tele-yoga group will participate in real-time yoga sessions three times a week for eight weeks, including individual sessions for the first two weeks and small group sessions for the remaining six weeks, with all sessions supervised by a certified instructor. Each session will last approximately 45-60 minutes and include a 5-10 minute warm-up, 15-20 minutes of yoga postures, 15-20 minutes of yogic breathing exercises, and 5-10 minutes of relaxation and meditation.
Study Locations (1 sites)
Department of Thoracic Surgery, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 65 years, * Histologically confirmed diagnosis of Stage I-IIIA lung cancer according to the 9th edition of the AJCC Cancer Staging Manual, * Underwent lobectomy, pneumonectomy, segmentectomy, or wedge resection via video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS), * An estimated life expectancy of ≥6 months, * Karnofsky Performance Status score greater than 80% at study entry, * Possession of the necessary equipment and access to a stable internet connection to enable participation in online interventions. Exclusion Criteria: * History of receiving radiotherapy or chemotherapy prior to surgery, * Presence of severe dysfunction in vital organs such as the heart, brain, kidneys, or others, * Having any comorbid condition that contraindicates participation in an exercise training program, * Presence of serious postoperative complications, * Cognitive impairments that hinder effective communication, * Current participation in a structured and regular exercise program, * Missing three consecutive weeks of sessions or completing less than 75% of the prescribed exercises, * Voluntary withdrawal from the study by the participant.
Conditions Hypertension, Atherosclerotic Cardiovasc...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In a multi-ethnic population, a genome-wide polygenic risk score (PRS) for systolic blood pressure (SBP), incorporating over one million common genetic variants, predicts blood pressure (BP) traits and the risk of adverse cardiovascular events beyond traditional risk factors. Delivering SBP PRS information to young and middle-aged adults with hypertension (HTN) and poor cardiovascular health (CVH) may enhance their motivation to adopt healthier lifestyles, improve blood pressure control, and ultimately reduce the risk of future cardiovascular disease (CVD). This randomized controlled trial will assess the impact of SBP PRS disclosure and theory-based genomic counseling on systolic blood pressure and health behaviors. A total of 300 adults aged 18-55 years will be enrolled and randomized to receive either routine clinical care or SBP PRS results with structured genomic counseling based on the Health Belief Model (HBM). Participants will be followed for 12 months. The primary outcome is change in 24-hour mean SBP from baseline to one year. Secondary outcomes include changes in physical activity, diet, medication adherence, smoking, lipid and glucose levels, and body composition. The study will also evaluate how behavior change is influenced by health beliefs, including perceived risk and self-efficacy. This study aims to advance the use of genomic tools in hypertension management and cardiovascular disease prevention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Regular Care — Educational brochures and lifestyle guidance on blood pressure control, medication adherence, physical activity, and healthy diet, provided at baseline only. No additional counseling or genetic risk disclosure will occur during the 12-month intervention period.
  • Behavioral: SBP PRS Dissemination — Participants receive individualized SBP PRS reports and structured genomic counseling sessions delivered by trained genetic counselors. Counseling addresses key constructs of the Health Belief Model, including perceived susceptibility, severity, and benefits of behavior change, with an emphasis on lifestyle modification and medication adherence.

Primary Outcomes

  • Change in Mean 24-Hour Systolic Blood Pressure (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-01
Completion: 2030-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Pankaj Arora, MD, FAHA (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Nehal Vekariya, MS
2059347173
nvekariya@uabmc.edu
Nehal Vekariya, MS
205-934-7173
nvekariya@uabmc.edu
University of Alabama at Birmingham
Pankaj Arora, MD
University of Alabama at Birmingham
Interventions
  • Behavioral: Regular Care — Educational brochures and lifestyle guidance on blood pressure control, medication adherence, physical activity, and healthy diet, provided at baseline only. No additional counseling or genetic risk disclosure will occur during the 12-month intervention period.
  • Behavioral: SBP PRS Dissemination — Participants receive individualized SBP PRS reports and structured genomic counseling sessions delivered by trained genetic counselors. Counseling addresses key constructs of the Health Belief Model, including perceived susceptibility, severity, and benefits of behavior change, with an emphasis on lifestyle modification and medication adherence.
Study Locations (1 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 to 55 years (inclusive) at the time of screening. * Diagnosis of hypertension defined by 2017 ACC/AHA guidelines, as evidenced by Resting office systolic blood pressure (SBP) of 130-160 mm Hg or Resting office diastolic blood pressure (DBP) of 80-100 mm Hg or Current use of antihypertensive medication. * Poor cardiovascular health, defined as Life's Essential 8 score \<50. * Willing and able to undergo 24-hour ambulatory blood pressure monitoring (ABPM) to confirm hypertension. * Able to provide informed consent. Exclusion Criteria: * History of cardiovascular disease, including Myocardial infarction, Angina, Cardiac arrhythmia, Coronary heart disease, Heart failure, Stroke, or transient ischemic attack. * Body mass index (BMI) \<18.5 kg/m² or \>45 kg/m². * Baseline office SBP \>160 mm Hg or DBP \>100 mm Hg. * Use of more than two antihypertensive medication classes. * Not hypertensive based on 24-hour ABPM (per 2017 ACC/AHA criteria). * Pregnant or breastfeeding. * Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m² (using CKD-EPI equation). * Urine albumin-to-creatinine ratio ≥30 mg/g. * Hepatic transaminase levels \>3× the upper limit of normal. * Significant psychiatric illness (assessed via Global Health Questionnaire-12). * Moderate or severe anxiety (Beck Anxiety Inventory \[BAI\] score \>16).
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase NA
Enrollment 86
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A Prospective Study on the Application of Lateral Decubitus Position in Patients with Left Breast Cancer Undergoing Adjuvant Radiotherapy

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Lateral Decubitus position — Lateral Decubitus position with a special device
  • Device: Lateral Decubitus device — Lateral Decubitus postion with a special device

Primary Outcomes

  • Radiotherapy Planning Dose-Volume Parameter -Volume of 5Gy heart dose (From study participation to the completion of the radiotherapy plan up to 2 years)
  • Radiotherapy Planning Dose-Volume Parameter -Max dose of LAD (From study participation to the completion of the radiotherapy plan up to 2 years)
  • Radiotherapy Planning Dose-Volume Parameter -mean heart dose (From study participation to the completion of the radiotherapy plan up to 2 years)
  • Major Cardiovascular Events (From the initiation of radiotherapy to 2 years after its completion.)
  • Subclinical Cardiovascular Events- Left ventricular ejection fraction (LVEF) (From the initiation of radiotherapy to 2 years after its completion.)
  • Subclinical Cardiovascular Events- Left ventricular diastolic dysfunction (From the initiation of radiotherapy to 2 years after its completion.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-14
Completion: 2028-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanfang Hospital, Southern Medical University
Contact Information
Study Contact:
hongmei Wang, phD
13189092896
hongmeiw18@163.com
hongmei Wang
+86-20-62787695
hongmeiw18@163.com
Nanfang Hospital, Southern Medical University
Hongmei Wang
86-20-62787695
hongmeiw18@163.com
Nanfang Hospital, Southern Medical University
Interventions
  • Device: Lateral Decubitus position — Lateral Decubitus position with a special device
  • Device: Lateral Decubitus device — Lateral Decubitus postion with a special device
Study Locations (2 sites)
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Provinse 510515 China
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Provinse 510515 China
Eligibility Criteria
Inclusion Criteria: * Voluntary signing of the informed consent form * Female patients aged 18-70 years * Newly diagnosed left-sided breast cancer confirmed by histopathology * No evidence of distant metastasis * Undergoing modified radical mastectomy or breast-conserving surgery * ECOG performance status of 0, 1, or 2 * Tolerance to radiotherapy * Radiation field covering the entire left breast/chest wall ± regional lymphatic drainage area Exclusion Criteria: * Bilateral breast cancer at diagnosis * History of breast reconstruction or implant placement on the affected side * Prior radiotherapy to the chest or supraclavicular region * Patients deemed unsuitable for the study based on the investigator's judgment
Conditions Refractory Lupus Nephritis, Systemic Scl...
Phase PHASE1, PHASE2
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) and other autoimmune diseases (AID) receive CD19-BCMA CAR T cell therapy. Phase I (Dose-Escalation/Dose-De-escalation Phase):The primary objective is to prospectively assess the safety of CD19-BCMA CAR T cell therapy in patients with SLE-LN, SSc, pSS-PAH and other autoimmune diseases (AID).Phase I (Dose-Escalation/Dose-De-escalation Phase):Primary Endpoint: Safety, tolerability, and determination of the optimal biological dose (OBD) and the Phase II recommended dose (RP2D) in patients with SLE-LN, SSc, pSS-PAH, and other autoimmune diseases (AID).Phase II (Dose-Expansion Phase):Overall remission rate (ORR) \[Time Frame: 90,180 Days\]

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CD19-BCMA CAR-T cells infusion — Approximately 3-5 days prior to CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.

Primary Outcomes

  • Phase I (Dose-Escalation/Dose-De-escalation Phase) (28 days;30 days)
  • Phase II (Dose-Expansion Phase) (90,180 Days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-04-18
Completion: 2026-07-31
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing GoBroad Hospital
Contact Information
Study Contact:
ZHOU
86+18511772961
zhousn@gobroadhealthcare.com
周胜男
18511772961
zhousn@gobroadhealthcare.com
北京高博医院
Interventions
  • Drug: CD19-BCMA CAR-T cells infusion — Approximately 3-5 days prior to CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
Study Locations (1 sites)
北京高博医院, Beijing, China,Beijing 102200 China
Eligibility Criteria
Inclusion Criteria 1. Refractory Lupus Nephritis(LN): Patients who meet all the following requirements can be enrolled in the group. Definition: Failure to achieve induction remission after 3 to 6 months of treatment with at least one immunosuppressive agent (including glucocorticoids, cyclophosphamide \[CTX\], tacrolimus, mycophenolate mofetil, and cyclosporine), accompanied by no reduction (or worsening) in proteinuria or persistent positive autoantibodies. Diagnostic criteria : According to the 2019 American College of Rheumatology (ACR) criteria, and confirmed by renal biopsy in accordance with the 2018 International Society of Nephrology (ISN)/Renal Pathology Society (RPS) criteria (Appendix 3), were diagnosed with active, proliferative lupus nephritis (LN), including Class III or IV \[excluding Class III (C), IV-S (C), and IV-G (C)\], or combined Class III/IV with Class V. 1. Male or female, aged 10-65 years; 2. Meeting the 2019 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria for Systemic Lupus Erythematosus (Appendix 4); 3. The ANA result is positive which means ANA titer≥ 1:80 (based on the equivalent detection results by Hep-2 immunofluorescence assay or enzyme immune assay), and/or according to the detection results from center laboratory, during the screening visit,the anti dsDNA serum antibody test is positive (based on ELISA assay, ≥30 IU/mL); 4. B cell CD19+ expression, and stop using immunosuppressant more than one week. 5. The lymphocyte count in the subject's blood routine \>0.5×109/L, and no contraindications for cell collection; 6. No serious allergic constitution; 7. ECOG score: 0-2: 8. Expected survival ≥90 days: Subjects and/or their guardian can understand and sign the informed consent form. 2\. SSc: Patients who meet all the following requirements can be enrolled in the group. 1. Patients or their legal representatives sign the informed consent form; 2. Male or female, aged 18-65 years. 3. According to the SSc classification criteria proposed by American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR), chose the highest score under the same condition. If the score ≥9, it can be classified SSc. (Appendix 5) 4. Satisfy a sufficient condition: the skin on the fingers of both hands is thickened and extend to the proximal end of metacarpophalangeal joint; 5. The lymphocyte count in the subject's blood routine \>0.5×109/L, and no contraindications for cell collection. 3\. pSS-PAH: Patients who meet all the following requirements can be enrolled in the group. 1. Patients or their legal representatives sign the informed consent form; 2. Male or female, aged 18-65 years; 3. Refractory connective tissue disease (PAH)patients: a) Satisfy the 2002 AECG or 2016 ACR/2016 EULAR classification criteria, can be diagnosed as pSS (Appendix 6); b) Confirmed by Right heart catheterization, satisfy the diagnose criteria of PAH: mPAP at rest ≥20mmHg; PAWP≤15mmHg; PVR at rest\>2WUs. 4. Low-risk patients whose PAH do not reach the risk stratification. The patients should meet: WHO cardiac function grading I-II; 6 minutes walking distance\>440 m; BNP\<50ng/L or NT-proBNP\<300ng/L; RAP\<8mmHg and CI≥2.5 L·min-1·m-2; 5. Subjects have received standard treatment in stable dose before first use of study drug, include: Glucocorticoids (prednisone 0-30mg/day, or other equivalent preparations) ≥4 weeks; Antimalarial drugs, single-agent immunosuppressants (MMF≤1.5g/day, AZP or 6-MP≤2mg/kg/day, MTX≤15mg/week, Leflunomide ≤ 20mg/day) ≥12 weeks, and do not add or change in 24 weeks after drug treatment; Use PAH target drugs \<3 before drug treatment(PGAs, ETRA,PDE-5 inhibiter, GCCA), and stable at least 4 weeks, and do not add or change in 24 weeks after drug treatment; 6. After clinician evaluate the disease condition of patients, they will allow using glucocorticoids no more than 10mg or other equivalent dose and stop all immunosuppressants (exclued hydroxychloroquine); 7. Reproductive-aged female patients with negative blood human chorionic gonadotropin (HCG) test within 7 days before trial pre-conduct treatment; Any child-bearing male and female patients must agree to take effective contraceptive method during the process of study and within at least 1 year after cell infusion. Child-bearing patients refer that he or she has the biological ability to born alive baby and have normal sex life. Female patients without the ability of born: hysterectomy or ovariectomy, or medically confirmed ovarian failure, or medically confirmed postmenopausal (without pathological or biological reason, amenorrhea last for at least 12 months); 8. Have appropriate organ function, the criteria are as follows: a) AST≤3 times upper limit of normal (ULN); b) ALT ≤3 times ULN; c) T-Bil ≤2 times ULN, unless the patient has a record of Gilbert syndrome; Patients with Gilbert syndrome can be enrolled satisfied the condition of Bil≤3 times ULN and DBIl ≤1.5 times ULN; d) Must have the lowest level of lung reserve, oxygen saturation under non-oxygen inhalation state \>95%; e) The lymphocyte count in the subject's blood routine \>0.5×109/L, and no contraindications for cell collection. 4.AID Definition: Based on the reliable laboratory test, it is confirmed that one or more definite disease-related antibodies in serum are positive, laboratory results and clinical symptoms have reasonable association. Including systemic lupus erythematosus, sjogren's syndrome, systemic sclerosis, rheumatoid arthritis, connective tissue diseases, overlap syndrome, etc. At the same time exclude other etiology may cause similar symptoms and signs, infections, malignant tumors, metabolic diseases, primary organ failure, etc. 1. Male or female, aged 10-65 years; Patients who do not meet the inclusive criteria of three groups above, meet any one below can be enrolled. 2. ANA titer\<1:80 (based on the equivalent detection results by Hep-2 immunofluorescence assay or enzyme immune assay), and/or during the screening visit, by the detection results from center laboratory, anti dsDNA serum antibody test is negative (based on ELISA assay, \<30 IU/mL); 3. In conventional therapy, occur recurrent infections, leading to intolerance of conventional therapy, but no active infection, serious infection(tuberculosis) currently; 4. Patients who cannot use drugs anymore, because of bone infarction, osteonecrosis, severe bone pain caused by long term use of drugs. 5. Patients who cannot use drugs anymore, because of vision changes, retinopathy, fundus hemorrhage caused by long term use of drugs. 6. Patients who cannot use drugs anymore, because of endocrine-related changes (premature closure of the femoral shaft, severe obesity, diabetes, impact on growth and development, etc.) caused by long term use of drugs. 7. Severe toxicity of blood system (≥grade3; neutrophil\<1\*10\^9/L,platelet\<50\*10\^9/L,hemoglobin\<80g/L); 8. Abnormal liver function (ALT ≥3 times ULN; ALT≥3 times ULN; T-Bil ≥2 times ULN); 9. After 3 months of regular treatment, there are still have disease progression (eg. urine protein index increased by 3 times); 10. Previously received CAR-T therapies, there are still have disease progression. Exclusion criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1\. Refractory Lupus Nephritis (LN): 1. Intracranial hypertension or disorder of consciousness; 2. Symptomatic heart failure or severe arrhythmia; 3. Symptoms of severe respiratory failure; 4. Complicated with other types of malignant tumors; 5. Diffuse intravascular coagulation; 6. Suffering from septicemia or other uncontrollable infections; 7. Patients with uncontrollable diabetes and other endocrine diseases; 8. Severe mental disorders; 9. Obvious and active intracranial lesions were detected by cranial magnetic resonance imaging (MRI); 10. Have received organ transplantation (excluding bone m
Conditions PIK3CA Mutation, HER2- Negative Breast C...
Phase PHASE3
Enrollment 540
Locations 231 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Zovegalisib — 400 mg orally BID administered daily on a 28-day treatment cycle
  • Drug: Capivasertib — 400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle
  • Drug: Fulvestrant — 500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)

Primary Outcomes

  • Progression-Free Survival (PFS) within the overall and kinase population by blinded independent central review (BICR) (The time from date of randomization until radiographic progression per RECIST v1.1, or death due to any cause, up to approximately 77 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-08-26
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Relay Therapeutics, Inc.
Contact Information
Study Contact:
Relay Therapeutics, Inc
617-322-0731
ClinicalTrials@relaytx.com
Interventions
  • Drug: Zovegalisib — 400 mg orally BID administered daily on a 28-day treatment cycle
  • Drug: Capivasertib — 400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle
  • Drug: Fulvestrant — 500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)
Study Locations (231 sites)
Banner MD Anderson Cancer Center, Gilbert, Arizona 85234 United States
Beverly Hills Cancer Center, Beverly Hills, California 90211 United States
City of Hope National Medical Center, Duarte, California 91010 United States
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
Stanford Women's Cancer Center, Palo Alto, California 94304 United States
University of California, Davis Comprehensive Cancer Center, Sacramento, California 95817 United States
University of California San Diego Moores Cancer Center, San Diego, California 92037 United States
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94158 United States
Kaiser Permanente Medical Center, Vallejo, California 94589 United States
Rocky Mountain Cancer Centers, LLP, Longmont, Colorado 80504 United States
Eligibility Criteria
Inclusion Criteria: * Patient has ECOG performance status of 0-1 * One or more known primary oncogenic PIK3CA mutation(s) * Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with a gonadotropin-releasing hormone (GnRH) agonist. Patients are to have commenced treatment with a GnRH agonist at least 2 weeks prior to randomization and must be willing to continue on it for the duration of the study. * Histologically or cytologically confirmed diagnosis of HR+/HER2- locally advanced or metastatic breast cancer (ABC) with radiological or objective evidence of recurrence or progression; locally advanced disease must not be amenable to resection with curative intent * Measurable disease per RECIST v1.1 or evaluable bone-only disease. * Must have radiological evidence of progression on or after previous treatment for HR+/HER2- ABC with: 1. At least 1 and no more than 2 lines of endocrine therapy (ET) in the (neo)adjuvant setting with recurrence on or within 12 months of completion or in the ABC setting 2. Only 1 prior line of CDK4/6 inhibitor therapy in one of the following settings: 1. CDK4/6 inhibitor + ET in the ABC setting 2. CDK4/6 inhibitor therapy in the adjuvant setting if progression occurred during or within 12 months of completion of adjuvant CDK4/6 inhibitor with ET 3. Patients who progressed during or within 12 months of completion of adjuvant CDK4/6 inhibitor and after receiving CDK4/6 inhibitor therapy in the advanced setting are considered to have had \>1 prior line of CDK4/6 inhibitor and are not eligible Exclusion Criteria: * Prior treatment with any of the following: 1. CDK2 inhibitors. Prior treatment with other investigational CDK inhibitors could be permitted upon discussion and approval from the Sponsor 2. PIK3, AKT, or mTOR inhibitors or any agent whose mechanism of action is the inhibit the PIK3/AKT/mTOR pathway 3. Immunotherapy 4. Antibody drug conjugates * Type 1 diabetes, or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or glycosylated hemoglobin (HbA1c) ≥7.0% (≥ 53 mmol/mol). * Clinically significant, uncontrolled cardiovascular disease * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events * Known active uncontrolled or symptomatic CNS metastases associated with progressive neurological symptoms or requiring ongoing corticosteroids or anticonvulsants for symptomatic control * Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease * History of hypersensitivity to fulvestrant or drugs in a similar class as fulvestrant, zovegalisib, or capivasertib, including their excipients * Known activating AKT mutations, loss-of-function PTEN mutations, or loss of PTEN expression resulting in oncogenic pathway activation downstream of PI3K
Conditions Craniosynostosis, Strabismus, Intracrani...
Phase Not Applicable
Enrollment 65
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Craniosynostosis are cranial deformations due to the premature closure of one or more cranial sutures. These deformations affect approximately one in 2.500 births. In most cases, craniosynostoses are isolated with unknown (non syndrome). On the other hand, 20% of these deformations are associated with other concentration (syndrome). Craniosynostosis has morphological (associated dysmorphism) and functional (growth conflict between the skull and the brain) repercussions. Ophthalmological disorders are frequent: refractive disorders, oculomotor disorders, optic nerve damage, sensory damage. This retrospective study aims to describe the ocular clinical characteristics associated with craniosynostosis in patients followed at the Amiens University Hospital.

Design

Study type: Observational Observational model: Case Only Time perspective: Retrospective

Primary Outcomes

  • Rate of strabismus and amblyopia (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-04
Completion: 2026-11
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 65 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire, Amiens
Contact Information
Study Contact:
Tran Thi Ha Chau, Pr
33+322089224
tran.chau@chu-amiens.fr
Mathilde Singlas, MD
33+322089200
singlas.mathilde@gmail.com
CHRU Amiens
Interventions
N/A
Study Locations (1 sites)
CHRU Amiens, Amiens, 80054 France
Eligibility Criteria
Inclusion Criteria: * Diagnosis of craniostenosis Exclusion Criteria: * Posterior plagiocephalia